http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 29 May 2026 16:17:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alto+Neuroscience%2C+Inc.+++For%3A+May+27++Filed+by%3A+Miller+Andrew+Craig/26575409.html si-local-file:///var/storage/secattach/20260529/26575409.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alto+Neuroscience%2C+Inc.+++For%3A+May+27++Filed+by%3A+Miller+Andrew+Craig/26575409.html Fri, 29 May 2026 16:17:00 -0400 ANRO O.61594251 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alto+Neuroscience%2C+Inc.+++For%3A+May+27++Filed+by%3A+Miller+Andrew+Craig/26575409.html si-local-file:///var/storage/secattach/20260529/26575409.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alto+Neuroscience%2C+Inc.+++For%3A+May+27++Filed+by%3A+Miller+Andrew+Craig/26575409.html Fri, 29 May 2026 16:17:00 -0400 ANRO O.61594251 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Alto+Neuroscience%2C+Inc.+++For%3A+May+27++Filed+by%3A+Miller+Andrew+Craig/26575360.html si-local-file:///var/storage/secattach/20260529/26575360.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Alto+Neuroscience%2C+Inc.+++For%3A+May+27++Filed+by%3A+Miller+Andrew+Craig/26575360.html Fri, 29 May 2026 16:16:00 -0400 ANRO O.61594251 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Alto+Neuroscience%2C+Inc.+++For%3A+May+27++Filed+by%3A+Miller+Andrew+Craig/26575360.html si-local-file:///var/storage/secattach/20260529/26575360.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Alto+Neuroscience%2C+Inc.+++For%3A+May+27++Filed+by%3A+Miller+Andrew+Craig/26575360.html Fri, 29 May 2026 16:16:00 -0400 ANRO O.61594251 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alto+Neuroscience%2C+Inc.+++For%3A+May+27/26561616.html si-local-file:///var/storage/secattach/20260528/26561616.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alto+Neuroscience%2C+Inc.+++For%3A+May+27/26561616.html Thu, 28 May 2026 08:18:00 -0400 ANRO O.61594251 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alto+Neuroscience%2C+Inc.+++For%3A+May+27/26561616.html si-local-file:///var/storage/secattach/20260528/26561616.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alto+Neuroscience%2C+Inc.+++For%3A+May+27/26561616.html Thu, 28 May 2026 08:18:00 -0400 ANRO O.61594251 http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html <p>Alto Neuroscience Inc. (NYSE: ANRO) announced the appointment of Andrew Miller to its board of directors, effective May 27, 2026.</p> <p>Miller founded Karuna Therapeutics and served as president of research and development, leading the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. He was the lead inventor of KarXT, now marketed as COBENFY for schizophrenia treatment, which represents the first novel mechanism approved for the indication in decades.</p> <p>At Karuna, Miller held multiple executive positions including chief operating officer and chief executive officer. He also served on the company's board of directors during the acquisition process.</p> <p>Miller currently serves http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html Thu, 28 May 2026 08:03:14 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html <p>Alto Neuroscience Inc. (NYSE: ANRO) announced the appointment of Andrew Miller to its board of directors, effective May 27, 2026.</p> <p>Miller founded Karuna Therapeutics and served as president of research and development, leading the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. He was the lead inventor of KarXT, now marketed as COBENFY for schizophrenia treatment, which represents the first novel mechanism approved for the indication in decades.</p> <p>At Karuna, Miller held multiple executive positions including chief operating officer and chief executive officer. He also served on the company's board of directors during the acquisition process.</p> <p>Miller currently serves http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html Thu, 28 May 2026 08:03:14 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html <p>Alto Neuroscience Inc. (NYSE: ANRO) announced the appointment of Andrew Miller to its board of directors, effective May 27, 2026.</p> <p>Miller founded Karuna Therapeutics and served as president of research and development, leading the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. He was the lead inventor of KarXT, now marketed as COBENFY for schizophrenia treatment, which represents the first novel mechanism approved for the indication in decades.</p> <p>At Karuna, Miller held multiple executive positions including chief operating officer and chief executive officer. He also served on the company's board of directors during the acquisition process.</p> <p>Miller currently serves http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html Thu, 28 May 2026 08:03:14 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html <p>Alto Neuroscience Inc. (NYSE: ANRO) announced the appointment of Andrew Miller to its board of directors, effective May 27, 2026.</p> <p>Miller founded Karuna Therapeutics and served as president of research and development, leading the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. He was the lead inventor of KarXT, now marketed as COBENFY for schizophrenia treatment, which represents the first novel mechanism approved for the indication in decades.</p> <p>At Karuna, Miller held multiple executive positions including chief operating officer and chief executive officer. He also served on the company's board of directors during the acquisition process.</p> <p>Miller currently serves http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html Thu, 28 May 2026 08:03:14 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html <p>Alto Neuroscience Inc. (NYSE: ANRO) announced the appointment of Andrew Miller to its board of directors, effective May 27, 2026.</p> <p>Miller founded Karuna Therapeutics and served as president of research and development, leading the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. He was the lead inventor of KarXT, now marketed as COBENFY for schizophrenia treatment, which represents the first novel mechanism approved for the indication in decades.</p> <p>At Karuna, Miller held multiple executive positions including chief operating officer and chief executive officer. He also served on the company's board of directors during the acquisition process.</p> <p>Miller currently serves http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html Thu, 28 May 2026 08:03:14 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html <p>Alto Neuroscience Inc. (NYSE: ANRO) announced the appointment of Andrew Miller to its board of directors, effective May 27, 2026.</p> <p>Miller founded Karuna Therapeutics and served as president of research and development, leading the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. He was the lead inventor of KarXT, now marketed as COBENFY for schizophrenia treatment, which represents the first novel mechanism approved for the indication in decades.</p> <p>At Karuna, Miller held multiple executive positions including chief operating officer and chief executive officer. He also served on the company's board of directors during the acquisition process.</p> <p>Miller currently serves http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html Thu, 28 May 2026 08:03:14 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html <p>Alto Neuroscience Inc. (NYSE: ANRO) announced the appointment of Andrew Miller to its board of directors, effective May 27, 2026.</p> <p>Miller founded Karuna Therapeutics and served as president of research and development, leading the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. He was the lead inventor of KarXT, now marketed as COBENFY for schizophrenia treatment, which represents the first novel mechanism approved for the indication in decades.</p> <p>At Karuna, Miller held multiple executive positions including chief operating officer and chief executive officer. He also served on the company's board of directors during the acquisition process.</p> <p>Miller currently serves http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html Thu, 28 May 2026 08:03:14 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html <p>Alto Neuroscience Inc. (NYSE: ANRO) announced the appointment of Andrew Miller to its board of directors, effective May 27, 2026.</p> <p>Miller founded Karuna Therapeutics and served as president of research and development, leading the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. He was the lead inventor of KarXT, now marketed as COBENFY for schizophrenia treatment, which represents the first novel mechanism approved for the indication in decades.</p> <p>At Karuna, Miller held multiple executive positions including chief operating officer and chief executive officer. He also served on the company's board of directors during the acquisition process.</p> <p>Miller currently serves http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html Thu, 28 May 2026 08:03:14 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html <p>Alto Neuroscience Inc. (NYSE: ANRO) announced the appointment of Andrew Miller to its board of directors, effective May 27, 2026.</p> <p>Miller founded Karuna Therapeutics and served as president of research and development, leading the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. He was the lead inventor of KarXT, now marketed as COBENFY for schizophrenia treatment, which represents the first novel mechanism approved for the indication in decades.</p> <p>At Karuna, Miller held multiple executive positions including chief operating officer and chief executive officer. He also served on the company's board of directors during the acquisition process.</p> <p>Miller currently serves http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html Thu, 28 May 2026 08:03:14 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html <p>Alto Neuroscience Inc. (NYSE: ANRO) announced the appointment of Andrew Miller to its board of directors, effective May 27, 2026.</p> <p>Miller founded Karuna Therapeutics and served as president of research and development, leading the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. He was the lead inventor of KarXT, now marketed as COBENFY for schizophrenia treatment, which represents the first novel mechanism approved for the indication in decades.</p> <p>At Karuna, Miller held multiple executive positions including chief operating officer and chief executive officer. He also served on the company's board of directors during the acquisition process.</p> <p>Miller currently serves http://www.streetinsider.com/Board+Changes/Alto+Neuroscience+adds+Karuna+founder+Miller+to+board/26561489.html Thu, 28 May 2026 08:03:14 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html <p class="bwalignc"> <i>Miller brings deep neuropsychiatry drug development and value creation experience, having led R&amp;D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. </p><p> “We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. “Few leaders http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html Thu, 28 May 2026 08:03:00 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html <p class="bwalignc"> <i>Miller brings deep neuropsychiatry drug development and value creation experience, having led R&amp;D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. </p><p> “We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. “Few leaders http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html Thu, 28 May 2026 08:03:00 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html <p class="bwalignc"> <i>Miller brings deep neuropsychiatry drug development and value creation experience, having led R&amp;D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. </p><p> “We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. “Few leaders http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html Thu, 28 May 2026 08:03:00 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html <p class="bwalignc"> <i>Miller brings deep neuropsychiatry drug development and value creation experience, having led R&amp;D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. </p><p> “We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. “Few leaders http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html Thu, 28 May 2026 08:03:00 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html <p class="bwalignc"> <i>Miller brings deep neuropsychiatry drug development and value creation experience, having led R&amp;D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. </p><p> “We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. “Few leaders http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html Thu, 28 May 2026 08:03:00 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html <p class="bwalignc"> <i>Miller brings deep neuropsychiatry drug development and value creation experience, having led R&amp;D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. </p><p> “We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. “Few leaders http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html Thu, 28 May 2026 08:03:00 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html <p class="bwalignc"> <i>Miller brings deep neuropsychiatry drug development and value creation experience, having led R&amp;D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. </p><p> “We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. “Few leaders http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html Thu, 28 May 2026 08:03:00 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html <p class="bwalignc"> <i>Miller brings deep neuropsychiatry drug development and value creation experience, having led R&amp;D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. </p><p> “We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. “Few leaders http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html Thu, 28 May 2026 08:03:00 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251 http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html <p class="bwalignc"> <i>Miller brings deep neuropsychiatry drug development and value creation experience, having led R&amp;D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. </p><p> “We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. “Few leaders http://www.streetinsider.com/Press+Releases/Alto+Neuroscience+Appoints+Karuna+Therapeutics+Founder+Andrew+Miller%2C+Ph.D.+to+Board+of+Directors/26561487.html Thu, 28 May 2026 08:03:00 -0400 A.03350906 A.41178514 A.50114120 A.60002469 ANRO O.01868273 O.02021666 O.13601449 O.41343427 O.61594251